Helus Pharma Partners with TARA Mind to Boost Veteran Recruitment in Phase 3 Depression Trial
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 trial of HLP003 for major depressive disorder, aligning with a recent executive order on mental health.
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a collaboration with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The partnership aims to expand mental health awareness within the veteran community while leveraging TARA Mind and VETS networks to enhance veteran engagement.
The announcement comes as Helus advances its FDA Breakthrough Therapy-designated HLP003 program, which is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. The collaboration aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, underscoring the importance of addressing unmet mental health needs in the veteran population.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. The company’s pipeline includes HLP003 for major depressive disorder and HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, along with an extensive research portfolio of investigational NSAs.
“The collaboration with TARA Mind and VETS is a critical step in ensuring that veterans, who often face significant mental health challenges, have access to potentially transformative treatments,” said a company spokesperson. The partnership is expected to accelerate recruitment for the PARADIGM program, which aims to provide durable improvements in mental health for those suffering from depression and anxiety.
The initiative also highlights the growing focus on mental health treatments for veterans, a demographic with high rates of major depressive disorder and other mental health conditions. By engaging with organizations like TARA Mind and VETS, Helus Pharma is tapping into established networks that can facilitate awareness and participation in clinical trials.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company’s website at www.helus.com or follow them on social media. The latest news and updates are available in the company’s newsroom at https://ibn.fm/HELP.